TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00619164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: E5555, 50 mg (tablet), taken orally, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: E5555, 100 mg (tablet), taken orally, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: E5555, 200 mg (tablet), taken orally, once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally, once a day.
Study: NCT04684875

Intervention type: DEVICE
Intervention: Radiofrequency Stylus
Description: Low power radiofrequency energy delivered to the posterior nasal nerve area
Study: NCT02671019

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guide to better alcohol habits
Description: A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guide to better alcohol habits
Description: A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
Study: NCT00743288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Same as above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study: NCT03464942

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months
Study: NCT00638209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT01325259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychologic assessment
Description: Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychologic assessment
Description: Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychologic assessment
Description: Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET
Description: intravenous injection of 4 MBq/kg of \[18F\]AV-45

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET
Description: intravenous injection of 4 MBq/kg of \[18F\]AV-45

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET
Description: intravenous injection of 4 MBq/kg of \[18F\]AV-45

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18-FDG PET
Description: intravenous injection of 100 to 120 MBq of FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18-FDG PET
Description: intravenous injection of 100 to 120 MBq of FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18-FDG PET
Description: intravenous injection of 100 to 120 MBq of FDG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging
Study: NCT03959904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small stitch
Description: Wound closure will be using small stiches or larger spaced stitches

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small stitch
Description: Wound closure will be using small stiches or larger spaced stitches

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A blood sample to look for biological markers of Hernia formation will be taken

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A blood sample to look for biological markers of Hernia formation will be taken

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Sample
Description: A tissue sample will be taken to measure markers of wound healing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Sample
Description: A tissue sample will be taken to measure markers of wound healing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Score
Description: A pain score will be recorded following the surgical procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Score
Description: A pain score will be recorded following the surgical procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Score
Description: A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Score
Description: A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
Study: NCT04263636

Intervention type: PROCEDURE
Intervention: Phacoemulsification with bilateral trifocal diffractive IOLs
Description: Uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs
Study: NCT04339010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercise
Description: The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypopressive exercise
Description: The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle contraction
Description: Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
Study: NCT00610233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation ON
Description: deep brain stimulation in the ON state

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation OFF
Description: Urodynamic investigation with deep brain stimulation in the OFF state
Study: NCT04631107

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose1- A
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose1- A
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose1- A
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose1- A
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose1- A
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose1- A
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose2- B
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose2- B
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose2- B
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose2- B
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose2- B
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose2- B
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo- C
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo- C
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo- C
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo- C
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo- C
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo- C
Description: Oral administration at bedtime
Study: NCT02012959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Study: NCT04536961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Treatment- BMS-986165-01
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Treatment- BMS-986165-01
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Specified quantity on specified days
Study: NCT04351126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.1 Milligrams (mg)
Description: 0.2-0.6 mg/day of fludrocortisone is prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.1 Milligrams (mg)
Description: 0.2-0.6 mg/day of fludrocortisone is prescribed

Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine
Description: 2.5 mg prescribed Vaginally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: 2.5 mg prescribed Vaginally twice daily
Study: NCT00565669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A Restasis®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A Restasis®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink tears
Description: blink tears to be used twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane
Description: systane to be used twice a day
Study: NCT03598582

Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Zeta
Description: Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol.
Study: NCT02272933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Slipper
Description: The shoe measures foot pressure and motion allowing gait to be quantified.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belt-Clip Sensor
Description: The sensor measures acceleration of the body allowing falls to be detected.
Study: NCT03723421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Injection Group Without Aspiration
Description: After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
Study: NCT02552498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: strangulation
Description: The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: strangulation
Description: The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: strangulation
Description: The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
Study: NCT03315611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'Eucerin AtopiControl Lotion' (for the body)
Description: Treatment with Eucerin AtopiControl Lotion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen challenge chamber
Description: Exposure to Dactylis glomerata pollen in an environmental challenge chamber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen challenge chamber
Description: Exposure to Dactylis glomerata pollen in an environmental challenge chamber

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen challenge chamber
Description: Exposure to Dactylis glomerata pollen in an environmental challenge chamber
Study: NCT03684421

Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy Rate
Description: The clinical pregnancy and live birth rate according to the protocol of COS

Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy Rate
Description: The clinical pregnancy and live birth rate according to the protocol of COS
Study: NCT06504888

Intervention type: DRUG
Intervention: Penicillin
Description: Compare whether there is a higher incidence of sinus elevation in patients allergic to penicillin compared to non-allergic patients, evaluating clinical histories.
Study: NCT04110717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestal Device
Description: Vestibular nerve stimulator

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Device
Description: Control Device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric Diet
Description: Hypocaloric diet

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hypocaloric Diet
Description: Hypocaloric diet
Study: NCT03266575

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation Exercise
Description: Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Based Exercise
Description: Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
Study: NCT01861418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic Manipulation
Description: Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham manipulation
Description: Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
Study: NCT03927677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanthine Oxidase Inhibitor
Description: LC350189 200mg qd
Study: NCT04454710

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency
Description: Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsed Radiofrequency
Description: Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.
Study: NCT00904839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: BIBF 1120 100 and 150 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBF 1120
Description: BIBF 1120 100 and 150 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFolfox
Description: standard i.v chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 100 mg/Kg solution , IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfox 6
Description: IV standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 100 mg/4 ml solution
Study: NCT00833118

Intervention type: PROCEDURE
Intervention: Jaw thrust maneuver (Intubation)
Description: Visualization of Larygnoscopic anatomy during intubation
Study: NCT01832818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuNec Cervical Disc
Description: Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
Study: NCT00796614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: Oral
Study: NCT05315154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No axillary surgery
Description: In the study arm will be omitted surgery in axilla

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLNB
Description: in the control arm will be realized SLNB
Study: NCT04016246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-Lipuro
Description: sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
Study: NCT02920814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.